Mayor Daniel Lurie joins 'Mad Money' host Jim Cramer to talk San Francisco's business outlook, the JPMorgan Healthcare ...

'Mad Money' host Jim Cramer weighs in on stock including: Anavex Life Sciences, Sarepta Therapeutics, Viking Therapeutics, ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

Jim Cramer, the host of Mad Money, recently highlighted a surge in merger activity, pointing out that we’ve seen a ...

Jim Cramer, the host of Mad Money, recently highlighted a surge in merger activity, pointing out that we’ve seen a ...

Jim Cramer is optimistic about top money-center bank stocks. These four look like outstanding ideas before their earnings ...

Jim Cramer, the host of Mad Money, recently shared his perspective on the stock market, especially reflecting on the events of 2024. He emphasized that years like 2024 don’t come around often ...

CNBC’s Jim Cramer examined Wednesday’s market rally and stressed that it’s important to stay focused on corporate earnings ...

Jim Cramer, the host of Mad Money, recently shared his perspective on the stock market, especially reflecting on the events of 2024. He emphasized that years like 2024 don’t come around often ...

JMP Securities analyst Ronald Josey maintained Lemonade with a Market Outperform and raised the price target from $40 to $60.

Lazard, Inc. LAZ is “really inexpensive,” the “Mad Money” host said. On Dec. 20, Keefe, Bruyette & Woods analyst Aidan Hall ...

Jim Cramer, the host of Mad Money, recently shared his perspective on the stock market, especially reflecting on the events of 2024. He emphasized that years like 2024 don’t come around often, where ...